Gilead CEO Sells 15,000 Shares; CFO and Executives Also Liquidate Small Holdings

Daniel Patrick O’Day, chairman and CEO of U.S. biotech firm Gilead Sciences, Inc. (NASDAQ: GILD), along with Chief Financial Officer Andrew Dickinson and other senior executives, sold portions of their stock under pre-established Rule 10b5-1 trading plans in early and mid-June.

On June 1, O’Day sold 15,000 shares of common stock in tranches at approximately $131–$133 per share, netting about $1.98 million (roughly KRW 2.7 billion) and reducing his holdings slightly from 632,567 shares to 617,567 shares. On June 15, CFO Andrew Dickinson and Head of Commercial & Corporate Affairs Johanna Mercier each sold around 3,000 shares, raising about $370,000–$380,000 apiece (around KRW 500 million), while both still retain remaining stakes valued at several billion won.

Gilead has been rapidly expanding its oncology and antiviral pipeline, including FDA approval for an expanded U.S. indication of Trodelvy for triple-negative breast cancer, development of a once-weekly oral HIV treatment and prevention regimen, and a proposed acquisition of cell-therapy company Arcellx. Amid these clinical and M&A developments and upward revisions to its 2026 revenue outlook, Gilead’s share price traded in the $120 range on the Nasdaq at the end of June, and its market capitalization stood at about $150 billion (around KRW 200 trillion).

Headquartered in California, Gilead is a major global pharmaceutical company focused on antiviral therapies for HIV and hepatitis B and C, as well as oncology drugs. Since 2019, O’Day has led the company, pursuing a strategy that emphasizes oncology and long-acting HIV treatment and prevention as its next growth pillars through targeted acquisitions and R&D investments.